Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

rials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' most recent Form 10-Q. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Condensed Consolidated Financial Statements

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands except per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues $-- $21,489 $-- $23,892

Operating expenses

Research and development(1) 7,581 7,602 19,091 21,275

General and administrative 2,084 2,444 6,104 6,844

Total operating expenses (2) 9,665 10,046 25,195 28,119

Interest income and other, net 316 864 1,311 2,855

Net (loss) income (2) $(9,349) $12,307 $(23,884) $(1,372)

Net (loss) income per share,

basic and diluted (2) $(0.32) $0.43 $(0.83) $(0.05)

Share used in calculating net

(loss) income per share,

basic and diluted
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Israel , May 24, 2013 ... leader in embolic protection stents, announced that Alan ... and Craig Shore , the Company,s Chief ... Investor Conference on Thursday May 30, 2013 at The Pfister ... The format of the conference includes a ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Many factors ... and uptake or efflux transporters at the blood-tissue barrier. ... related to unbound fractions in the tissue rather than ... these disposition challenges is required to guide lead optimization, ... identify any species-dependent variables that may impact the likely ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Quincy ... discovery and development of calcium-binding proteins to support ... safety assessment study of apoaequorin in ... journal published for the British Industrial Biological Research ... was to investigate potential adverse effects, if any, ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. ... company focused on obtaining FDA clearance and commercializing its ... announced the pricing of an underwritten public offering of ... to purchase 3,500,000 shares of its common stock at ... combined public offering price of $1.25 per share and ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... JERUSALEM and NEEDHAM, Massachusetts, October 15 /PRNewswire-FirstCall/,-- ... launching at this week,s American,Society of Anesthesiologists ... total,solution Microstream(R) Monitoring System (MSM(TM)), powered by ... wireless technology for,continuous central station monitoring, is ...
... PALO ALTO, Calif., Oct. 15 Telik, Inc.,(Nasdaq: ... and Drug Administration (FDA),has removed the partial hold ... follows a complete review of TELCYTA data by,the ... development. Telik, Inc. of Palo Alto, CA ...
... Lower Dose Associated with Fewer Adverse Events in Healthy ... ... (NYSE: GSK ) HIV protease inhibitor LEXIVA(R),(fosamprenavir calcium) may now be ... of protease inhibitors in the,bloodstream. The U.S. Food and Drug Administration ...
Cached Biology Technology:Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 2Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 3Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 4FDA Removes Partial Hold on TELCYTA Clinical Development 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 3FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 4
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
(Date:5/22/2013)... and engineers must join together in a major new ... a crisis in providing Earth,s people with clean water ... focus of a comment article in the current edition ... newsmagazine of the American Chemical Society (ACS), the world,s ... L. Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... assistant at the University of North Carolina Hospitals arrived ... a glowing track record in helping to repair heart ... perform gastric bypass operations for morbid obesity. , The ... Surgical System, manufactured by Intuitive Surgical. UNC currently is ...
... University of North Carolina Hospitals arrived in February sporting ... record in helping to repair heart valves, remove cancerous ... operations for morbid obesity. , The new arrival is ... by Intuitive Surgical. UNC currently is the only gynecological ...
... aquatic plants respond to plant disease and climate ... say plant pathologists with The American Phytopathological Society ... University, Ithaca, NY, many aquatic plants possess unique ... study, plant pathologists may be able to apply ...
Cached Biology News:FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 2FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 3Screen all at risk for HIV, plus pregnant women 2Screen all at risk for HIV, plus pregnant women 3